The company's pipeline includes four clinical-stage candidates, including a treatment for COVID-19, a taste-masked formulation for inborn errors of metabolism, a treatment for vascular Ehlers-Danlos syndrome, and a treatment for induced Vasomotor Symptoms. Acer's products have a comparatively de-risked profile, with a favorable safety profile, clinical proof-of-concept data, and accelerated paths for development. The company is committed to time and cost-efficient drug development and has a strong company culture that values individual rights, hard work, fosters creativity, and promotes success.